CN103041161A - 用于治疗急性湿疹的内服中药组合物及其制备方法 - Google Patents
用于治疗急性湿疹的内服中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN103041161A CN103041161A CN2012105936517A CN201210593651A CN103041161A CN 103041161 A CN103041161 A CN 103041161A CN 2012105936517 A CN2012105936517 A CN 2012105936517A CN 201210593651 A CN201210593651 A CN 201210593651A CN 103041161 A CN103041161 A CN 103041161A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- radix
- rhizoma
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 141
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 51
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 50
- 230000001154 acute effect Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 41
- 229940079593 drug Drugs 0.000 claims abstract description 51
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 32
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 32
- 235000008434 ginseng Nutrition 0.000 claims abstract description 32
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 22
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 134
- 210000000582 semen Anatomy 0.000 claims description 72
- 239000000843 powder Substances 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000012153 distilled water Substances 0.000 claims description 45
- 239000000706 filtrate Substances 0.000 claims description 43
- 241000208340 Araliaceae Species 0.000 claims description 31
- 240000008669 Hedera helix Species 0.000 claims description 31
- 238000005325 percolation Methods 0.000 claims description 28
- 239000010231 banlangen Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 11
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 11
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 11
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 42
- 239000000739 antihistaminic agent Substances 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 230000010354 integration Effects 0.000 abstract description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001387 anti-histamine Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241001116477 Adenophora triphylla Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 240000008365 Celosia argentea Species 0.000 abstract 1
- 235000000722 Celosia argentea Nutrition 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 241000735527 Eupatorium Species 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 241001506304 Kadsura japonica Species 0.000 abstract 1
- 241000737253 Lygodium japonicum Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000012874 Phaseolus calcaratus Nutrition 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000534017 Saururus chinensis Species 0.000 abstract 1
- 241000046198 Triteleia hyacinthina Species 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 240000001417 Vigna umbellata Species 0.000 abstract 1
- 235000011453 Vigna umbellata Nutrition 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 description 31
- 210000000214 mouth Anatomy 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 210000000952 spleen Anatomy 0.000 description 23
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 210000004072 lung Anatomy 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 16
- 210000002216 heart Anatomy 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 230000036407 pain Effects 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 235000009508 confectionery Nutrition 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 206010011224 Cough Diseases 0.000 description 14
- 238000003304 gavage Methods 0.000 description 13
- 239000013641 positive control Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 206010040882 skin lesion Diseases 0.000 description 10
- 231100000444 skin lesion Toxicity 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 229940124623 antihistamine drug Drugs 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000001047 pyretic effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 6
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 6
- 206010040943 Skin Ulcer Diseases 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 231100000019 skin ulcer Toxicity 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000475481 Nebula Species 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000013116 chronic cough Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 3
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000447727 Scabies Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000001723 curing Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 208000017574 dry cough Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960001660 histamine phosphate Drugs 0.000 description 3
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 3
- 229960003088 loratadine Drugs 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010052369 Encephalitis lethargica Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 229940074869 marquis Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 206010058483 Nuchal rigidity Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034240 Pelvic congestion Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000013007 heat curing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | n | 耳肿胀度(mg) |
模型对照组 | 20 | 6.49+0.93 |
阳性对照组 | 20 | 4.19+1.06 |
治疗组1 | 20 | 1.17+0.59 |
治疗组2 | 20 | 1.70+0.47 |
治疗组3 | 20 | 1.53+0.72 |
治疗组4 | 20 | 1.36+0.68 |
空白对照组 | 20 | 0.31+0.09 |
组别 | n | 耳肿胀度(mg) |
模型对照组 | 20 | 7.33+0.83 |
阳性对照组 | 20 | 5.61+0.75 |
治疗组1 | 20 | 1.86+0.39 |
治疗组2 | 20 | 2.37+0.65 |
治疗组3 | 20 | 2.12+0.79 |
治疗组4 | 20 | 2.07+0.41 |
空白对照组 | 20 | 0.35+0.14 |
组别 | n | CGRP(pg/mL) |
模型对照组 | 20 | 13.71+2.01 |
阳性对照组 | 20 | 20.49+1.57 |
治疗组5 | 20 | 31.02+1.88 |
治疗组6 | 20 | 26.39+2.61 |
治疗组7 | 20 | 27.79+2.14 |
治疗组8 | 20 | 29.31+1.93 |
空白对照组 | 20 | 34.17+2.61 |
组别 | n | 痒阈值(μg) |
模型对照组 | 10 | 29.13+3.41 |
阳性对照组 | 10 | 69.51+2.71 |
治疗组9 | 10 | 119.22+3.05 |
治疗组10 | 10 | 102.99+3.71 |
治疗组11 | 10 | 105.61+2.99 |
治疗组12 | 10 | 110.27+3.76 |
组别 | n | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) |
治疗组 | 120 | 71 | 27 | 13 | 9 | 92.5 |
对照组 | 108 | 41 | 35 | 10 | 22 | 79.6 |
组别 | n | 治疗前 | 治疗后 |
治疗组 | 120 | 8.1+1.6 | 1.1+0.3 |
对照组 | 108 | 7.9+1.6 | 2.9+0.7 |
组别 | 痊愈数 | 复发数 | 复发率(%) |
治疗组 | 71 | 3 | 4.23 |
对照组 | 41 | 7 | 17.07 |
组别 | n | 瘙痒消失时间(d) | 皮疹消退时间(d) |
治疗组 | 120 | 3.5+0.9 | 5.3+1.1 |
对照组 | 108 | 7.0+0.8 | 9.2+2.0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210593651.7A CN103041161B (zh) | 2012-12-29 | 2012-12-29 | 用于治疗急性湿疹的内服中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210593651.7A CN103041161B (zh) | 2012-12-29 | 2012-12-29 | 用于治疗急性湿疹的内服中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103041161A true CN103041161A (zh) | 2013-04-17 |
CN103041161B CN103041161B (zh) | 2014-06-18 |
Family
ID=48054172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210593651.7A Expired - Fee Related CN103041161B (zh) | 2012-12-29 | 2012-12-29 | 用于治疗急性湿疹的内服中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103041161B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398892A (zh) * | 2014-11-30 | 2015-03-11 | 顾蔷怡 | 一种治疗湿疮的药物及其制备方法 |
CN105169150A (zh) * | 2015-10-30 | 2015-12-23 | 江崇礼 | 一种用于治疗急性湿疹的中药组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1214261A (zh) * | 1998-10-21 | 1999-04-21 | 余际康 | 一种治疗皮肤病的口服药 |
CN101199683A (zh) * | 2006-12-12 | 2008-06-18 | 沈阳澳华制药有限公司 | 一种治疗皮肤病的中药及其制备方法 |
CN101984995A (zh) * | 2010-07-02 | 2011-03-16 | 荣成市科学技术情报研究所 | 一种治疗婴儿湿疹的中药组合物 |
-
2012
- 2012-12-29 CN CN201210593651.7A patent/CN103041161B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1214261A (zh) * | 1998-10-21 | 1999-04-21 | 余际康 | 一种治疗皮肤病的口服药 |
CN101199683A (zh) * | 2006-12-12 | 2008-06-18 | 沈阳澳华制药有限公司 | 一种治疗皮肤病的中药及其制备方法 |
CN101984995A (zh) * | 2010-07-02 | 2011-03-16 | 荣成市科学技术情报研究所 | 一种治疗婴儿湿疹的中药组合物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398892A (zh) * | 2014-11-30 | 2015-03-11 | 顾蔷怡 | 一种治疗湿疮的药物及其制备方法 |
CN105169150A (zh) * | 2015-10-30 | 2015-12-23 | 江崇礼 | 一种用于治疗急性湿疹的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN103041161B (zh) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041184B (zh) | 用于治疗婴幼儿慢性湿疹的中药组合物及其制备方法 | |
CN103520694B (zh) | 治疗慢性阻塞性肺病稳定期的中药组合物及其制备方法 | |
CN105535715A (zh) | 治疗湿热内蕴型湿疹的中药外洗液 | |
CN102895528B (zh) | 用于治疗脾肺气虚型过敏性鼻炎的中药及其制备方法 | |
CN102716339B (zh) | 治疗尿毒症的中药组合物、其制备方法及应用 | |
CN102166240B (zh) | 治疗肛门直肠疾病的中药组合物及其制备方法 | |
CN103520593A (zh) | 一种治疗滴虫性阴道炎的中药制剂及其制备方法 | |
CN104524071A (zh) | 一种治疗原发性肾病的药物组合物及其用途 | |
CN103041161B (zh) | 用于治疗急性湿疹的内服中药组合物及其制备方法 | |
CN103028060B (zh) | 用于治疗婴幼儿急性湿疹的中药组合物及其制备方法 | |
CN103212031A (zh) | 用于治疗原发性肾病综合征的中药组合物及其制备方法 | |
CN105213807A (zh) | 用于治疗阴虚火旺型复发性口腔溃疡的药物 | |
CN104706953A (zh) | 一种治疗慢性子宫颈炎的中药制剂 | |
CN104784549A (zh) | 用于治疗变应性鼻炎的内服中药 | |
CN103041194B (zh) | 用于治疗慢性湿疹的中药组合物及其制备方法 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN103028045B (zh) | 用于治疗急性湿疹的外用中药组合物及其制备方法 | |
CN102895519B (zh) | 用于治疗过敏性鼻炎的中药及其制备方法 | |
CN103110756B (zh) | 一种治疗肾性血尿的中药组合物 | |
CN104840902A (zh) | 一种治疗卵巢肿瘤的中药制剂 | |
CN104398789A (zh) | 一种治疗缺铁性贫血的中药汤剂 | |
CN103656063A (zh) | 用于治疗慢性前列腺炎的药物 | |
CN103028046A (zh) | 用于治疗萎缩性鼻炎的中药组合物及其制备方法 | |
CN102671021B (zh) | 一种治疗慢性卡他性中耳炎的中药及制备方法 | |
CN105288054A (zh) | 治疗脾肾阳虚证型肠易激综合征的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Han Min Inventor before: The inventor has waived the right to be mentioned |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: REQUEST NOT TO RELEASE THE NAME TO: HAN MIN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171024 Address after: Lang Jun Center No. 28 road 401120 Chongqing city Yubei District Huanglong longta Street Building 3 2-1 Patentee after: Chongqing AOPO Ruisen Technology Co. Ltd. Address before: 266071 Shandong province Qingdao City Road No. 19 east red room unit 7 Patentee before: Qingdao Hengbo Instrument Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180327 Address after: 401120 Chongqing Yubei District Hui Xing Street Xingke Road No. 293 with mountain name 7 9 Patentee after: CHONGQING XUANNU BIOTECHNOLOGY CO., LTD. Address before: Lang Jun Center No. 28 road 401120 Chongqing city Yubei District Huanglong longta Street Building 3 2-1 Patentee before: Chongqing AOPO Ruisen Technology Co. Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 Termination date: 20181229 |
|
CF01 | Termination of patent right due to non-payment of annual fee |